FY2026 Earnings Estimate for TWST Issued By William Blair

Twist Bioscience Co. (NASDAQ:TWST) – Equities research analysts at William Blair issued their FY2026 EPS estimates for shares of Twist Bioscience in a research report issued to clients and investors on Monday, November 18th. William Blair analyst M. Larew forecasts that the company will post earnings per share of ($1.50) for the year. The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.56) per share.

Several other equities analysts have also weighed in on the stock. Barclays cut their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday. Evercore ISI lifted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Robert W. Baird lifted their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $51.78.

Twist Bioscience Trading Up 1.9 %

TWST opened at $41.89 on Wednesday. Twist Bioscience has a 12-month low of $23.07 and a 12-month high of $60.90. The firm has a market capitalization of $2.49 billion, a PE ratio of -11.57 and a beta of 1.78. The firm has a 50 day moving average of $43.93 and a two-hundred day moving average of $46.15.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Signaturefd LLC increased its stake in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC purchased a new stake in Twist Bioscience during the second quarter worth about $43,000. Blue Trust Inc. increased its stake in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in Twist Bioscience during the second quarter worth about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the period.

Insider Activity

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,730 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total value of $81,206.20. Following the transaction, the chief executive officer now owns 495,523 shares of the company’s stock, valued at $23,259,849.62. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Dennis Cho sold 659 shares of the company’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $27,388.04. Following the completion of the transaction, the insider now directly owns 94,481 shares in the company, valued at $3,926,630.36. The trade was a 0.69 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is currently owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.